Complete Filing Data
AEON Biopharma, Inc. reported Net Income Loss of -$39.22 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean AEON Biopharma, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Net Income * | -$39.2M | $42.0M | -$52.6M | $8.2M | -$3.6K |
| Operating Income Loss | -$12.8M | $73.0M | -$48.4M | -$1.9M | -$3.6K |
| Nonoperating Income Expense | -$26.4M | -$31.0M | -$4.1M | $10.1M | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$39.2M | $42.0M | -$52.6M | $8.2M | |
| Operating Expenses | $12.8M | -$73.0M | $48.4M | ||
| Selling General And Administrative Expense | $12.2M | $13.6M | $13.7M | ||
| Other Nonoperating Income Expense | $290.0K | $95.0K | $289.0K | ||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | ||
| Research And Development Expense | $4.1M | $14.2M | $34.8M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$4.5M | -$6.6M | $9.1M | -$6.2M | $164.1M | -$118.0M | -$297.7M | -$15.4M | -$17.6M | -$10.4M | $1.9M | $2.8M | $5.7M | -$4.0M | $6.3M |
| Operating Income Loss | -$2.5M | -$4.3M | -$462.0K | -$4.0M | $153.5M | -$74.2M | -$283.7M | -$14.0M | -$13.0M | -$9.9M | -$427.2K | -$389.1K | -$450.9K | -$398.4K | -$200.9K |
| Nonoperating Income Expense | -$2.0M | -$2.3M | $9.6M | -$2.2M | $10.6M | -$43.9M | -$14.0M | -$1.4M | -$4.6M | -$525.0K | $2.3M | $3.2M | $6.1M | -$3.6M | $6.5M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$4.5M | -$6.6M | $9.1M | -$6.2M | $164.1M | -$118.0M | -$297.7M | -$15.4M | -$17.6M | -$10.4M | $1.9M | $2.8M | $5.7M | -$4.0M | |
| Operating Expenses | $2.5M | $4.3M | $462.0K | $4.0M | -$153.5M | $74.2M | $283.7M | $14.0M | $13.0M | $9.9M | |||||
| Selling General And Administrative Expense | $1.9M | $3.3M | $3.1M | $3.0M | $3.3M | $4.6M | $5.3M | $4.9M | $3.8M | $2.4M | |||||
| Other Nonoperating Income Expense | $68.0K | $92.0K | $103.0K | $19.0K | $34.0K | $39.0K | $186.0K | $45.0K | $64.0K | $141.0K | |||||
| Income Tax Expense Benefit | $0.00 | $91.7K | $404.6K | $0.00 | $17.0K | ||||||||||
| Research And Development Expense | $597.0K | $1.1M | $825.0K | $972.0K | $4.4M | $5.7M | $6.4M | $9.0M | $9.2M | $7.5M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity * | -$55.0M | -$28.6M | -$153.0M | -$287.5M | -$223.8M | $21.4K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $3.0M | $13.0K | $5.2M | $5.1M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $3.0M | -$5.1M | $4.6M | $497.4K | ||
| Retained Earnings Accumulated Deficit | -$470.8M | -$431.6M | -$473.6M | -$474.8M | -$17.0M | -$3.6K |
| Liabilities | $60.6M | $31.7M | $159.9M | $143.2M | $17.9M | $59.6K |
| Liabilities Current | $6.9M | $14.1M | $13.0M | $82.6M | $834.6K | $59.6K |
| Liabilities And Stockholders Equity | $5.6M | $3.1M | $6.8M | $10.8M | $276.9M | $81.0K |
| Assets | $5.6M | $3.1M | $6.8M | $10.8M | $276.9M | $81.0K |
| Assets Current | $3.4M | $1.6M | $6.2M | $9.8M | $835.2K | |
| Cash And Cash Equivalents At Carrying Value | $3.0M | $13.0K | $5.2M | $9.7M | ||
| Common Stock Value | $9.0K | $4.0K | $4.0K | $14.0K | ||
| Property Plant And Equipment Net | $162.0K | $235.0K | $332.0K | $431.0K | ||
| Prepaid Expense And Other Assets Current | $392.0K | $1.6M | $1.1M | $92.0K | ||
| Other Assets Noncurrent | $948.0K | $29.0K | $29.0K | $34.0K | ||
| Other Accrued Liabilities Current | $1.7M | $3.6M | $3.6M | $740.0K | ||
| Operating Lease Right Of Use Asset | $1.1M | $1.3M | $262.0K | $475.0K | ||
| Employee Related Liabilities Current | $2.9M | $1.1M | $943.0K | $1.1M | ||
| Accrued Clinical Trails Expenses Current | $1.4M | $3.6M | $5.1M | $2.1M | ||
| Accounts Payable Current | $942.0K | $5.9M | $3.4M | $7.8M | ||
| Accounts Payable And Accrued Liabilities Current | $634.6K | $21.0K | ||||
| Change In Amount Of Contingent Consideration Liability | -$3.5M | -$100.8M | ||||
| Temporary Equity Accretion To Redemption Value Adjustment | $2.5M | $26.4M | ||||
| Interest Earned On Cash Held In Trust Account | $3.7M | $79.7K | ||||
| Assets Held In Trust Noncurrent | $276.1M | |||||
| Operating Lease Liability Noncurrent | $893.0K | $1.1M | $242.0K | |||
| Convertible Long Term Notes Payable | $34.6M | $11.7M | $60.4M | |||
| Temporary Equity Carrying Amount Attributable To Parent | $276.0M | |||||
| Increase Decrease Franchise Tax Payable | $321.4K | $200.0K | ||||
| Contingent Consideration Liability | $42.0K | $3.5M | $104.4M | |||
| Franchise Tax Payable | $200.0K | |||||
| Repayments Of Notes Payable | $73.8K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | -$19.9M | -$15.9M | -$11.3M | -$28.6M | -$32.1M | -$27.9M | -$198.4M | -$153.0M | -$121.7M | -$11.5M | -$7.3M | -$11.6M | -$12.4M | -$14.2M | -$16.9M | -$17.2M | -$22.8M | -$18.8M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $5.9M | $8.4M | $10.4M | $537.0K | $3.4M | $1.6M | $2.6M | $4.7M | $9.7M | $22.2M | $7.8K | $166.2K | $663.5K | $988.9K | $1.4M | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $10.4M | -$3.6M | -$15.1M | -$5.1M | -$331.2K | $1.4M | ||||||||||||||
| Retained Earnings Accumulated Deficit | -$433.7M | -$429.1M | -$422.5M | -$433.7M | -$427.5M | -$591.6M | -$423.1M | -$11.5M | -$7.4M | -$11.6M | -$12.4M | -$14.2M | -$17.2M | $2.3M | $5.0M | |||||
| Liabilities | $28.6M | $27.5M | $25.1M | $36.1M | $33.7M | $201.4M | $139.4M | $12.1M | $7.9M | $12.0M | $12.8M | $14.8M | $22.2M | $24.5M | $21.0M | |||||
| Liabilities Current | $8.2M | $9.1M | $8.6M | $10.7M | $10.4M | $16.0M | $14.2M | $9.5M | $5.9M | $1.3M | $965.8K | $791.8K | $223.5K | $206.4K | $468.0K | |||||
| Liabilities And Stockholders Equity | $8.7M | $11.7M | $13.8M | $4.0M | $5.7M | $3.0M | $17.6M | $21.8M | $21.6M | $277.3M | $276.5M | $276.6M | $277.2M | $277.6M | $278.1M | |||||
| Assets | $8.7M | $11.7M | $13.8M | $4.0M | $5.7M | $3.0M | $17.6M | $21.8M | $21.6M | $277.3M | $276.5M | $276.6M | $277.2M | $277.6M | $278.1M | |||||
| Assets Current | $7.4M | $10.3M | $12.3M | $2.4M | $4.0M | $2.5M | $16.9M | $592.1K | $542.4K | $166.2K | $248.3K | $518.5K | $1.0M | $1.4M | $2.1M | $81.0K | ||||
| Cash And Cash Equivalents At Carrying Value | $5.9M | $8.4M | $10.4M | $537.0K | $3.4M | $1.6M | $16.2M | $27.8K | $7.8K | $166.2K | $497.4K | $663.5K | $988.9K | $1.4M | ||||||
| Common Stock Value | $9.0K | $9.0K | $9.0K | $4.0K | $4.0K | $4.0K | $4.0K | $308.00 | ||||||||||||
| Property Plant And Equipment Net | $181.0K | $200.0K | $220.0K | $258.0K | $282.0K | $307.0K | $356.0K | |||||||||||||
| Prepaid Expense And Other Assets Current | $1.5M | $1.8M | $1.9M | $1.8M | $577.0K | $940.0K | $734.0K | |||||||||||||
| Other Assets Noncurrent | $29.0K | $29.0K | $29.0K | $29.0K | $29.0K | $29.0K | $29.0K | |||||||||||||
| Other Accrued Liabilities Current | $2.6M | $3.0M | $2.8M | $3.2M | $3.8M | $4.1M | $2.9M | |||||||||||||
| Operating Lease Right Of Use Asset | $1.1M | $1.2M | $1.2M | $1.3M | $1.4M | $198.0K | $323.0K | |||||||||||||
| Employee Related Liabilities Current | $1.5M | $546.0K | $429.0K | $1.6M | $1.2M | $1.3M | $1.0M | |||||||||||||
| Accrued Clinical Trails Expenses Current | $1.5M | $1.7M | $3.0M | $1.4M | $2.3M | $984.0K | $5.6M | |||||||||||||
| Accounts Payable Current | $2.5M | $3.9M | $2.4M | $4.6M | $3.0M | $6.5M | $4.0M | |||||||||||||
| Accounts Payable And Accrued Liabilities Current | $7.0M | $4.0M | $2.6M | $943.8K | $848.8K | $741.8K | $70.0K | |||||||||||||
| Change In Amount Of Contingent Consideration Liability | -$37.0K | $16.0K | -$3.5M | $0.00 | -$161.2M | $63.8M | -$75.9M | |||||||||||||
| Temporary Equity Accretion To Redemption Value Adjustment | $200.9K | -$2.9M | $825.1K | $79.7K | $26.4M | |||||||||||||||
| Interest Earned On Cash Held In Trust Account | $1.7M | $129.6K | $8.3K | |||||||||||||||||
| Assets Held In Trust Noncurrent | $21.2M | $21.1M | $279.4M | $277.2M | $276.3M | $276.1M | $276.1M | $276.0M | $276.0M | |||||||||||
| Operating Lease Liability Noncurrent | $957.0K | $1.0M | $1.1M | $1.2M | $1.3M | $52.0K | ||||||||||||||
| Convertible Long Term Notes Payable | $17.1M | $15.2M | $13.3M | $15.2M | $13.3M | $5.1M | ||||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | $21.2M | $21.0M | $278.5M | $276.9M | $276.1M | $276.0M | $276.0M | $245.2M | ||||||||||||
| Increase Decrease Franchise Tax Payable | $50.0K | |||||||||||||||||||
| Contingent Consideration Liability | $32.0K | $69.0K | $53.0K | $6.9M | $6.9M | $168.1M | $74.5M | |||||||||||||
| Franchise Tax Payable | $16.2K | $30.0K | $226.9K | $150.0K | $100.0K | |||||||||||||||
| Repayments Of Notes Payable | $73.8K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$17.3M | -$20.3M | -$35.6M | -$1.5M | |
| Net Cash Provided By Used In Financing Activities | $20.3M | $15.1M | $40.5M | $278.0M | |
| Share Based Compensation | $5.3M | $6.3M | $5.9M | ||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.2M | $513.0K | $66.0K | ||
| Increase Decrease In Other Operating Capital Net | $952.0K | -$120.0K | $174.0K | ||
| Increase Decrease In Accrued Expenses And Other Liabilities | -$2.2M | -$1.4M | -$105.0K | ||
| Increase Decrease In Accounts Payable | -$5.0M | $2.5M | $6.6M | ||
| Net Cash Provided By Used In Investing Activities | -$4.0K | -$306.0K | -$276.0M | ||
| Depreciation Depletion And Amortization | $78.0K | $97.0K | $68.0K | ||
| Proceeds From Convertible Debt | $15.0M | $44.5M | |||
| Increase Decrease In Accrued Liabilities | $2.0M | $613.6K | $3.6K | ||
| Increase Decrease In Prepaid Expense | -$331.1K | $372.4K | |||
| Proceeds From Notes Payable | $150.0K | $35.2K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q3 2023 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$7.9M | -$8.6M | -$15.1M | -$11.1M | -$411.7K | -$554.5K |
| Net Cash Provided By Used In Financing Activities | $18.3M | $5.0M | $6.0M | $278.0M | ||
| Share Based Compensation | $1.7M | $1.6M | $2.2M | $1.4M | ||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $298.0K | -$124.0K | $363.0K | -$39.0K | ||
| Increase Decrease In Other Operating Capital Net | $3.0K | -$64.0K | $6.0K | -$40.0K | ||
| Increase Decrease In Accrued Expenses And Other Liabilities | -$2.0M | -$3.2M | -$1.7M | $4.0M | ||
| Increase Decrease In Accounts Payable | -$3.5M | $3.1M | -$3.7M | -$3.5M | ||
| Net Cash Provided By Used In Investing Activities | -$4.0K | $260.0M | $80.5K | -$276.0M | ||
| Depreciation Depletion And Amortization | $19.0K | $25.0K | $21.0K | $25.0K | ||
| Proceeds From Convertible Debt | $5.0M | $6.0M | ||||
| Increase Decrease In Accrued Liabilities | $1.4M | $107.3K | $293.2K | |||
| Increase Decrease In Prepaid Expense | $44.0K | -$20.1K | $696.8K | |||
| Proceeds From Notes Payable | $35.2K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Earnings Per Share Diluted | $-3.95 | $72.93 | $-0.38 | |||
| Earnings Per Share Basic | $-3.95 | $77.74 | $-0.38 | |||
| Weighted Average Number Of Shares Outstanding Basic | 9.9M | 540.4K | 138.8M | |||
| Weighted Average Number Of Diluted Shares Outstanding | 9.9M | 575.9K | 138.8M | |||
| Common Stock Shares Authorized | 1.04B | 500.0M | 500.0M | 207.5M | ||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Common Stock Shares Outstanding | 12.1M | 555.5K | 516.4K | 138.8M | ||
| Common Stock Shares Issued | 12.1M | 555.5K | 516.4K | 138.8M | ||
| Preferred Stock Shares Issued | 0.00 | 0.00 | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | ||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | ||||
| Preferred Stock Shares Authorized | 1.0M | 1.0M | ||||
| Temporary Equity Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share Diluted | $-0.39 | $-0.60 | $2.28 | $-11.24 | $304.00 | $-227.87 | $-8.01 | $-0.11 | $-0.13 | $-0.08 | ||||||
| Earnings Per Share Basic | $-0.39 | $-0.60 | $2.28 | $-11.24 | $304.00 | $-227.87 | $-8.01 | $-0.11 | $-0.13 | $-0.08 | ||||||
| Weighted Average Number Of Shares Outstanding Basic | 11.6M | 11.1M | 4.0M | 549.2K | 539.8K | 517.9K | 37.2M | 138.8M | 138.8M | 138.8M | ||||||
| Weighted Average Number Of Diluted Shares Outstanding | 11.6M | 11.1M | 4.0M | 549.2K | 539.8K | 517.9K | 37.2M | 138.8M | 138.8M | 138.8M | ||||||
| Common Stock Shares Authorized | 1.04B | 1.04B | 1.04B | 500.0M | 500.0M | 500.0M | 500.0M | |||||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||
| Common Stock Shares Outstanding | 11.6M | 11.5M | 10.5M | 39.6M | 39.1M | 38.1M | 37.2M | |||||||||
| Common Stock Shares Issued | 11.6M | 11.5M | 10.5M | 39.6M | 39.1M | 38.1M | 37.2M | |||||||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||
| Preferred Stock Shares Authorized | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | |||||||
| Temporary Equity Par Or Stated Value Per Share | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2016 |
|---|---|---|---|---|---|---|---|
| Additional Paid In Capital | $415.8M | $403.0M | $381.3M | $187.3M | $32.0K | $24.3K | |
| Fair Value Adjustment Of Warrants | -$84.9M | $14.7M | -$6.7M | -$10.7M | |||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $5.3M | $6.3M | $6.0M | ||||
| Change In Fair Value Of Convertible Notes | -$22.9M | $3.3M | -$4.4M | ||||
| Operating Costs And Expenses | $3.3M | $1.9M | $3.6K | ||||
| Investment Income Interest | $3.7M | $79.7K | |||||
| Loss And Comprehensive Loss | -$52.6M | ||||||
| Change In Fair Value Of Forward Purchase Agreement And Derivative | $19.7M | ||||||
| Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares | 7.4M | ||||||
| Warrants And Rights Outstanding | $3.3M | $1.2M | $1.4M | $800.0K | |||
| Prepaid Expense Current | $337.8K | ||||||
| Unrealized Gain On Change In Fair Value Of Warrants | $10.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional Paid In Capital | $413.8M | $413.3M | $411.2M | $401.6M | $399.6M | $393.2M | $362.1M | $32.0K | $32.0K | $32.0K | $32.0K | $32.0K | $32.0K | $2.7M | -$1.3M | ||
| Fair Value Adjustment Of Warrants | $236.0K | $542.0K | -$86.7M | $377.0K | -$5.9M | $20.9M | -$1.6M | $524.1K | $142.9K | -$2.2M | -$3.0M | -$7.2M | |||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $414.0K | $1.6M | $1.7M | $1.6M | $1.7M | $1.6M | $2.2M | $1.1M | $1.4M | $1.1M | |||||||
| Change In Fair Value Of Convertible Notes | -$1.9M | -$1.9M | -$1.6M | -$1.9M | $1.8M | -$87.0K | -$13.2M | -$1.5M | -$4.7M | -$666.0K | |||||||
| Operating Costs And Expenses | $3.5M | $1.7M | $488.1K | $427.2K | $389.1K | $450.9K | $398.4K | $200.9K | |||||||||
| Investment Income Interest | $200.0K | $1.7M | $1.2M | $137.4K | $129.6K | $21.4K | $28.7K | $8.3K | |||||||||
| Loss And Comprehensive Loss | $164.1M | -$118.0M | $43.9M | -$15.4M | -$17.6M | -$10.4M | |||||||||||
| Change In Fair Value Of Forward Purchase Agreement And Derivative | -$81.0K | -$2.9M | $22.9M | $15.8M | |||||||||||||
| Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares | 1.3M | 812.6K | 669.8K | 961.4K | 2.2M | 4.4M | 8.5M | 14.6M | 10.9M | 0.00 | |||||||
| Warrants And Rights Outstanding | $2.3M | $2.1M | $2.0M | $1.8M | $1.5M | $12.0M | $2.2M | ||||||||||
| Prepaid Expense Current | $150.7K | $85.3K | $41.3K | $138.4K | $240.5K | $352.3K | $364.7K | $391.5K | $696.8K | ||||||||
| Unrealized Gain On Change In Fair Value Of Warrants | $1.2M | $2.2M | $3.0M | $6.1M | -$3.7M | $7.2M |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.